Skip to main content
Erschienen in: Clinical Rheumatology 1/2012

01.01.2012 | Letter to the Editor

Expanded role for interleukin-17 in rheumatoid arthritis

verfasst von: Feng-Lai Yuan, Xia Li, Cheng-Wan Li, Rui-Sheng Xu, Jun-Ming Sun

Erschienen in: Clinical Rheumatology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
1.
Zurück zum Zitat Metawi SA, Abbas D, Kamal MM, Ibrahim MK (2011) Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 30(9):1201–1207PubMedCrossRef Metawi SA, Abbas D, Kamal MM, Ibrahim MK (2011) Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 30(9):1201–1207PubMedCrossRef
2.
Zurück zum Zitat Li X, Yuan FL, Lu WG, Zhao YQ, Li CW, Li JP, Xu RS (2010) The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun 397(2):131–135PubMedCrossRef Li X, Yuan FL, Lu WG, Zhao YQ, Li CW, Li JP, Xu RS (2010) The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun 397(2):131–135PubMedCrossRef
3.
Zurück zum Zitat Ryu S, Lee JH, Kim SI (2006) IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 25(1):16–20PubMedCrossRef Ryu S, Lee JH, Kim SI (2006) IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 25(1):16–20PubMedCrossRef
4.
Zurück zum Zitat Paradowska A, Masliniski W, Grzybowska-Kowalczyk A, Lacki J (2007) The function of interleukin 17 in the pathogenesis of rheumatoid arthritis. Arch Immunol Ther Exp (Warsz) 55(5):329–334CrossRef Paradowska A, Masliniski W, Grzybowska-Kowalczyk A, Lacki J (2007) The function of interleukin 17 in the pathogenesis of rheumatoid arthritis. Arch Immunol Ther Exp (Warsz) 55(5):329–334CrossRef
5.
Zurück zum Zitat van den Berg WB, Miossec P (2009) IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 5(10):549–553PubMedCrossRef van den Berg WB, Miossec P (2009) IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 5(10):549–553PubMedCrossRef
6.
Zurück zum Zitat Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, Fitzgerald O, Bresnihan B, Veale DJ, Fearon U (2009) Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther 11(4):R113PubMedCrossRef Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, Fitzgerald O, Bresnihan B, Veale DJ, Fearon U (2009) Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther 11(4):R113PubMedCrossRef
7.
Zurück zum Zitat Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P (1999) Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42(5):963–970PubMedCrossRef Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P (1999) Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42(5):963–970PubMedCrossRef
Metadaten
Titel
Expanded role for interleukin-17 in rheumatoid arthritis
verfasst von
Feng-Lai Yuan
Xia Li
Cheng-Wan Li
Rui-Sheng Xu
Jun-Ming Sun
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 1/2012
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1869-0

Weitere Artikel der Ausgabe 1/2012

Clinical Rheumatology 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.